tiprankstipranks
Trending News
More News >
Beyond Medical Technologies Inc (TSE:DOCT)
:DOCT

Beyond Medical Technologies Inc (DOCT) AI Stock Analysis

Compare
40 Followers

Top Page

TSE:DOCT

Beyond Medical Technologies Inc

(DOCT)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 5.2)
Rating:42Neutral
Price Target:
C$0.25
▲(4.17% Upside)
The score is held down primarily by weak financial performance—ongoing losses, negative cash flow, and missing revenue since 2022—plus added financing risk from the TTM debt increase. Technicals are also negative with the price below major moving averages and a negative MACD, while valuation offers little support given the loss-driven negative P/E and no dividend.
Positive Factors
Equity recovery
The shift from negative equity in 2023–24 to positive TTM equity (1,881,812) materially improves solvency and balance-sheet flexibility. A sustained positive equity base enhances the company’s ability to raise capital, absorb losses and negotiate with creditors, supporting longer-term operations and strategic options.
Reduced cash burn trend
Operating and free cash flow remain negative, but TTM FCF (-470,326) is an improvement versus 2023 (-527,044) and far better than 2020–2022. This trend signals progress in reducing cash burn and, if sustained, lengthens runway and reduces dependency on external financing for ongoing operations.
Narrowing losses in 2024
Net losses narrowed materially in 2024 (near breakeven at -285), indicating tangible operating improvement versus historically deep losses. If management sustains cost discipline and revenue recovery, this trajectory increases the probability of restoring durable profitability and completing a structural turnaround.
Negative Factors
No revenue since 2022
Reported revenue is zero from 2022 through the TTM period, removing visibility into product-market demand and undermining the core business model. Without recurring sales, the company must rely on financing rather than operating income, a structural risk to sustainability and any revenue-driven recovery plan.
Persistent negative cash generation
TTM operating cash flow and free cash flow are both negative (~-470k) and the firm reported TTM EBIT -1.2M and net loss -1.73M. Persistent negative cash generation and large operating losses threaten runway, increase dilution/refinancing needs, and impair the company’s ability to self-fund growth or capex.
Rapid debt increase and prior solvency issues
Total debt spiked to 1,266,258 in the TTM period from 60,000 in 2024 while equity was negative in 2024 (-620,659). This sudden leverage increase and prior solvency shortfall raise refinancing and interest-risk, constraining financial flexibility and elevating long-term funding vulnerability.

Beyond Medical Technologies Inc (DOCT) vs. iShares MSCI Canada ETF (EWC)

Beyond Medical Technologies Inc Business Overview & Revenue Model

Company DescriptionRepublic Technologies, Inc. engages in the manufacturing of personal protective equipment. It operates through the following segments: Corporate, PPE Sector, and Waste Treatment. The company was founded by Bharath Bhushan on November 29, 2006 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyBeyond Medical Technologies Inc generates revenue through the sale of its proprietary medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also monetizes its telemedicine platforms through subscription models and partnerships with healthcare institutions. Additionally, Beyond Medical Technologies Inc engages in strategic collaborations with pharmaceutical companies and research institutions to co-develop and license new technologies, contributing to its revenue streams.

Beyond Medical Technologies Inc Financial Statement Overview

Summary
Overall fundamentals are high risk: persistent operating losses (TTM EBIT -1,196,986; net income -1,726,132), consistently negative operating/free cash flow (TTM OCF/FCF about -470k), and no reported revenue from 2022 through TTM. Balance sheet improved to positive equity in TTM (1,881,812) but the sharp rise in debt (TTM 1,266,258) and prior negative equity keep financial quality weak.
Income Statement
8
Very Negative
Operating performance is weak and volatile. The company generated revenue in 2020–2021 (2021 revenue: 943,425), but revenue is reported as 0 from 2022 through TTM (Trailing-Twelve-Months), limiting visibility into the business model and demand. Profitability is consistently negative: TTM (Trailing-Twelve-Months) EBIT is -1,196,986 and net income is -1,726,132, and 2021 margins were deeply negative (net margin about -268%). Losses narrowed materially in 2024 (net income near breakeven at -285) but widened again in the TTM period, signaling uneven cost control and an incomplete turnaround.
Balance Sheet
22
Negative
The balance sheet shows mixed signals with elevated risk. Equity was negative in 2023–2024 (2024 equity: -620,659), which is a red flag for solvency and financial flexibility, but it improves to positive in TTM (Trailing-Twelve-Months) (equity: 1,881,812) alongside a much larger asset base (assets: 7,141,568). Total debt rises sharply in TTM (Trailing-Twelve-Months) to 1,266,258 (from 60,000 in 2024), increasing leverage and refinancing risk despite the equity recovery. Overall, the recent improvement in equity is a positive, but the rapid step-up in debt and history of negative equity keep balance-sheet quality below average.
Cash Flow
14
Very Negative
Cash generation remains pressured. Operating cash flow is negative across all periods, including TTM (Trailing-Twelve-Months) at -470,330, implying the business is still consuming cash to operate. Free cash flow is also negative in TTM (Trailing-Twelve-Months) (-470,326), though it is less negative than 2023 (-527,044) and far better than 2020–2022 levels, indicating some progress in reducing cash burn. However, the company still appears dependent on external funding (debt/equity issuance) until operating cash flow turns sustainably positive.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.00943.42K208.66K
Gross Profit0.000.000.000.00-250.00K-73.24K
EBITDA-1.46M-365.88K-37.96K-773.00K-1.34M-6.35M
Net Income-1.73M-285.00-596.00K-1.40M-2.91M-6.52M
Balance Sheet
Total Assets7.14M13.80K95.64K608.18K1.95M1.84M
Cash, Cash Equivalents and Short-Term Investments7.06M13.22K64.14K536.75K1.43M624.21K
Total Debt1.27M60.00K30.00K0.0085.09K165.01K
Total Liabilities5.26M634.46K430.35K346.94K413.28K361.85K
Stockholders Equity1.88M-620.66K-334.72K261.25K1.54M1.48M
Cash Flow
Free Cash Flow-470.33K-109.77K-527.04K-894.01K-1.47M-2.07M
Operating Cash Flow-470.33K-109.77K-527.04K-894.01K-1.40M-1.83M
Investing Cash Flow-2.97M0.000.000.00-467.99K-260.27K
Financing Cash Flow5.53M30.00K30.00K0.002.67M-65.96K

Beyond Medical Technologies Inc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.24
Price Trends
50DMA
0.29
Negative
100DMA
0.42
Negative
200DMA
0.45
Negative
Market Momentum
MACD
-0.01
Negative
RSI
42.67
Neutral
STOCH
45.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.29, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.67 is Neutral, neither overbought nor oversold. The STOCH value of 45.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.

Beyond Medical Technologies Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
42
Neutral
C$8.03M-3.00-319.50%-55.56%
42
Neutral
C$475.25K-1.4719.70%
40
Underperform
C$3.31M-35.16-1.36%-144.44%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:DOCT
Beyond Medical Technologies Inc
0.24
0.22
1075.00%
TSE:APL
Appulse
0.23
<0.01
3.21%
TSE:ATMO
Atmofizer Technologies Inc. Class B
0.06
-0.08
-59.26%

Beyond Medical Technologies Inc Corporate Events

Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Republic Technologies Expands ETH Holdings and Infrastructure
Positive
Dec 11, 2025

Republic Technologies Inc. has significantly expanded its ETH holdings, now totaling 1,570.60 ETH, and has seen a 23% appreciation in value. This expansion is part of their strategy to strengthen their infrastructure and enhance their capacity for generating attestations that safeguard data integrity. The company employs ‘Synthetic Mining’ strategies to acquire ETH at lower prices and generate additional revenue without issuing new equity. These efforts, alongside their recent OTCQB listing and secured convertible note facility, position Republic to scale its validator operations and increase attestation output, aligning with their mission to leverage Ethereum technology for data integrity.

Private Placements and Financing
Republic Technologies Secures Initial US$10 Million from Convertible Note Facility
Positive
Dec 8, 2025

Republic Technologies Inc. has successfully completed the first drawdown of its US$100 million secured convertible note facility, raising US$10 million. The funds will primarily be used to acquire Ethereum to support the company’s validator infrastructure and attestation services. The issuance included 27,904,000 common share purchase warrants, potentially providing an additional US$10 million if fully exercised. This move strengthens Republic’s position in the Ethereum infrastructure sector, with no new control person created and necessary shareholder approvals obtained.

Business Operations and StrategyDelistings and Listing Changes
Republic Technologies Expands U.S. Market Presence with OTCQB Listing
Positive
Dec 4, 2025

Republic Technologies Inc. has announced its listing on the OTCQB Venture Market in the United States under the ticker symbol DOCKF, with its shares now eligible for electronic clearing through the Depository Trust Company. This move is part of the company’s strategy to increase visibility and participation among U.S. investors, enhancing its reach to a broader pool of retail and institutional investors. The company’s business model, which leverages Ethereum’s Proof-of-Stake upgrade, allows it to operate in an asset-light manner, minimizing overhead and reducing operational risks. This strategic positioning amid market volatility aims to generate diversified revenue streams while maintaining risk-disciplined exposure to the technological ecosystem.

Business Operations and StrategyPrivate Placements and Financing
Republic Technologies Secures $100M Convertible Note Facility to Boost Ethereum Infrastructure
Positive
Nov 21, 2025

Republic Technologies Inc. has entered into a definitive investment agreement for a secured convertible note facility worth up to US$100 million with an institutional investor. The financing will support the company’s blockchain-based attestation platform and validator infrastructure, aligning with its strategy to accumulate Ethereum (ETH) and enhance its network infrastructure. The facility includes a 24-month term with a 0% interest rate and a 10% original issue discount, secured by ETH collateral. The first drawdown of US$10 million is expected to close by December 5, 2025, with further drawdowns and top-up tranches available under certain conditions. The company plans to allocate 90% of the proceeds to acquire ETH, with the remainder for general working capital.

Business Operations and StrategyExecutive/Board Changes
Republic Technologies Announces Strategic Management Appointments
Positive
Oct 31, 2025

Republic Technologies Inc., a company involved in technology and investment sectors, has announced key management appointments and corporate developments for Q3 2025. The company appointed Mr. Tianrui Zhang as an independent director and Ms. Litong Cao as Director and Secretary. These strategic appointments are expected to enhance the company’s growth and digital transformation efforts, positioning it for future success in its industry.

Private Placements and Financing
Republic Technologies Inc. Proposes $100 Million Convertible Note Facility
Positive
Oct 20, 2025

Republic Technologies Inc. has announced a proposed financing agreement with an institutional investor for a secured convertible note facility of up to US$100 million. The financing, which includes an initial US$10 million tranche, is aimed at supporting the company’s blockchain-based attestation platform and validator infrastructure. The facility will be secured by ETH collateral and offers convertible notes that can be exchanged for common shares. The funds are intended to enhance Republic’s validator infrastructure and attestation services, with additional proceeds allocated for general working capital.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 14, 2026